Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.39 AUD -2.5% Market Closed
Market Cap: 136.3m AUD
Have any thoughts about
Paradigm Biopharmaceuticals Ltd?
Write Note

Paradigm Biopharmaceuticals Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Paradigm Biopharmaceuticals Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Common Stock
AU$238.1m
CAGR 3-Years
17%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Common Stock
$1.3B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Common Stock
$557m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Common Stock
AU$168.8m
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
2%
Telix Pharmaceuticals Ltd
ASX:TLX
Common Stock
AU$446.3m
CAGR 3-Years
39%
CAGR 5-Years
44%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Common Stock
AU$230.6m
CAGR 3-Years
22%
CAGR 5-Years
30%
CAGR 10-Years
19%
No Stocks Found

Paradigm Biopharmaceuticals Ltd
Glance View

Market Cap
136.6m AUD
Industry
Biotechnology

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

PAR Intrinsic Value
0.43 AUD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Paradigm Biopharmaceuticals Ltd's Common Stock?
Common Stock
238.1m AUD

Based on the financial report for Jun 30, 2024, Paradigm Biopharmaceuticals Ltd's Common Stock amounts to 238.1m AUD.

What is Paradigm Biopharmaceuticals Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
17%

Over the last year, the Common Stock growth was 13%. The average annual Common Stock growth rates for Paradigm Biopharmaceuticals Ltd have been 17% over the past three years , 17% over the past five years .

Back to Top